Product: Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100)
Issue: Health product – product quality
What to do: Check your product or contact your pharmacist to determine if it is recalled. If you have a recalled product, do not use it and return it to your pharmacy for a replacement product and proper disposal. If you have used the recalled product and have health concerns, contact your healthcare provider. Go to the hospital immediately if you develop difficulty breathing, chest pain or confusion.
Who this is for: General public
Taro Zoledronic acid injection 5mg/100mL
Issue Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.
Zoledronic acid is a prescription drug used to treat and prevent osteoporosis and to treat Paget's disease (a condition that disrupts the normal cycle of bone renewal).
If particulate matter is injected into a patient, there is potential for injury, such as inflammation or irritation of the veins, infections at the site of injection or in other parts of the body, allergic reactions, and the formation of blood clots that can move to other parts of the body. In the most serious cases, blood clots could move to the lungs and cause lung damage (pulmonary embolism), which can be permanent or fatal. Patients who have been treated with a recalled drug should go to the hospital immediately if they develop difficulty breathing, chest pain or confusion.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
Check your product or contact your pharmacist to determine if it is affected. If you have a recalled product, do not use it and return it to your pharmacy for a replacement product and proper disposal.
If you have used the recalled product and have health concerns, contact your healthcare provider. Go to the hospital immediately if you develop difficulty breathing, chest pain or confusion.
Contact Taro Pharmaceuticals Inc. by calling toll free at 1-800-268-1975 if you have questions about this recall.
Report any health product adverse events or complaints to Health Canada.
Alert / recall type: Public Advisory Category: Health products – Drugs Published by: Health Canada
Également disponible en français
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/09/c2850.html
UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock
The U.S. Centers For Disease Control and Prevention has relaxed some guidelines around COVID-19, including the quarantine recommendation for people who have been exposed. Officials say the new guidelines are meant to educate people on how to stay safe without causing much disruption to life, school and work.
A new class of drugs developed by Eli Lilly and Novo Nordisk have shown striking results in studies, letting many people safely lose 20% of their weight. If insurers step up to back them, the drugs—and the stocks—could take off.
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court of Delaware has issued a decision in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. finding certain XIFAXAN® (rifaximin) 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid. As previously stated, the Company will
Only 65% of Black adults aged 50 and older are up-to-date with potentially life-saving colorectal cancer screening. We proudly supported the development of the National Colorectal Cancer Roundtable...
Four years after Siga Technologies (Nasdaq: SIGA) gained approval for a smallpox drug, the Corvallis company is gearing up to get the same antiviral into a clinical trial for monkeypox. Tpoxx, also known as tecovirimat, is the only drug available to treat the virus, though it is not yet approved in the U.S. for the disease. The Food and Drug Administration designated Tpoxx as an investigational drug for monkeypox, allowing it to be released from the Strategic National Stockpile only after prescribers jump through considerable hoops.
The polio virus has been found in New York City sewage, but officials are stressing that the highest risk is for people who haven’t been vaccinated. Polio was once one of the nation’s most feared diseases, with annual outbreaks causing thousands of cases of paralysis. Recently, an unvaccinated young adult north of New York City contracted polio.
The Supreme Court decision to overturn Roe v Wade triggered a wave of outrage from pro-choice groups as states moved quickly to criminalize abortion. Now, investors are taking action with their dollars, deploying capital to support women’s health startups.
Sanofi, GSK, and Haleon had big market drops for two straight days after UBS weighed in with a downgrade of Sanofi.
After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer.
The pandemic may have taught Americans more about the potential of primary care than anything they’d experienced in an exam room in the past.
Brian Bonds was one of the first reported cases of MPV in Nevada — and hopes speaking out will help reduce its stigma.
Why is my anxiety worse in the morning? Here, three women explain why they feel more anxious in the morning and a doctor gives their advice. Morning anxiety...
The Pensacola community has been mourning the death of SCI business director Rodney Jackson from Vibrio. Here's what to know about the bacteria.
CMV, a common virus, that can be asymptomatic can cause birth defects, deaths when babies are born with it. No vaccine yet. Awareness and prevention are best.
Zantac, also sold as ranitidine, was pulled from the market in 2020 following a study that suggested it contained a cancer-causing impurity.
STORY: Johnson & Johnson is discontinuing its controversial talc-based baby powder globally in 2023, after years of battling consumer lawsuits over alleged carcinogens in the product.In a statement, J&J said Thursday it would transition to a cornstarch-based baby powder which is already sold in several countries around the world.J&J already stopped selling its talc baby powder in the U.S. and Canada back in 2020, saying demand had fallen in the wake of what it called "misinformation" about the product's safety amid a string of legal challenges.The company faces some 38,000 lawsuits from consumers claiming its talc products were contaminated with asbestos and caused cancer.J&J denies the allegations and reiterated that on Thursday, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.Evidence of asbestos contamination was confirmed in a 2018 Reuters investigation which found that J&J knew for decades that the carcinogen was present in its products, according to internal company records, trial testimony and other evidence.In response to media reports of contamination evidence, J&J has repeatedly said in court and Congress that its talc products are safe and do not cause cancer.The company has attempted to alleviate legal troubles by creating a subsidiary unit and immediately seeking bankruptcy protection, putting a hold on pending lawsuits.Those suing have said Johnson & Johnson should have to defend itself against the lawsuits, while defendants of J&J and the bankrupt subsidiary process say it is an equitable way to compensate claimants.